Creative Biolabs has announced a significant expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that promises to accelerate biomedical discovery by providing researchers with more comprehensive tools to dissect cellular heterogeneity. The upgraded suite of services is designed to meet the escalating demand for high-resolution cellular profiling, offering end-to-end workflows that range from single-cell transcriptome profiling to integrated multimodal and multi-omics analyses. This expansion matters because it directly addresses a fundamental shift in life science research: the transition from bulk tissue profiling to single-cell resolution. Such a shift is essential for identifying rare cell subpopulations, characterizing complex tumor microenvironments, and tracing cell lineage trajectories—capabilities that are increasingly indispensable in fields like oncology, immunology, and neuroscience.
At the core of the expanded offering are robust, high-throughput single-cell RNA sequencing services that deliver high sensitivity and coverage across thousands of individual cells. These services provide high-resolution transcriptomic insights from diverse fresh biological specimens, enabling researchers to capture subtle gene expression differences that might be obscured in bulk analysis. However, the company also recognizes the long-standing laboratory challenge of processing complex, fibrous, or biobanked archival samples. To address this, Creative Biolabs now features specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. For tissues where single-cell dissociation is prone to cell damage, dissociation-induced stress responses, or selective loss of fragile cell types—such as human brain, myocardium, or flash-frozen clinical biopsies—the optimized single-cell nuclei RNA sequencing service isolates intact nuclei. This approach bypasses harsh enzymatic dissociation, minimizing artifacts while retaining informative nuclear RNA profiles, thereby dramatically expanding the scope of clinical translational research.
Beyond single-dimensional analysis, Creative Biolabs is advancing its high-throughput single-cell multi-omics service, which allows simultaneous interrogation of genomic variations, epigenomic landscapes (e.g., chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, this integrated platform empowers researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity. As a senior scientist at Creative Biolabs explained, understanding biology at single-cell and single-nucleus resolution is no longer a luxury—it is fundamental to precision medicine and biomarker discovery. The company's goal is to provide a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support.
Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide. This expansion not only reinforces the company's commitment to cutting-edge single-cell technologies but also equips the global research community with the tools needed to unravel the complexities of human disease. By enabling more accurate and comprehensive cellular profiling, these services have the potential to accelerate the development of new diagnostics and therapeutics, ultimately benefiting patients through improved precision medicine approaches.
